Forward-Looking Statement

This presentation contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Eastwood Bio-Medical Canada Inc. (the Company) and the Company’s affiliates, including expectations and assumptions concerning TSX Venture Exchange approvals. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.
Disclaimer

Although the data found in this Investor Deck have been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding accuracy, adequacy, completeness, legality, reliability or usefulness of any information. This disclaimer applies to both isolated and aggregate uses of the information. The information is provided on an "as is" basis.

Changes may be periodically made to the information herein; these changes may or may not be incorporated in any new versions of this Investor Deck. It is recommended that careful attention be paid to the contents of any information associated with a file, and that the originator of the data or information be contacted with any questions regarding appropriate use. If you find any errors or omissions, please report them to info@eastwoodcos.com.

Notwithstanding claims or statements made by any officer, director, employee, related party, or affiliate of Eastwood Bio-medical Canada in any form including written or verbal, EBM makes no claims regarding any products it distributes or manufactures except for the sanctioned claims referred to in slide 4 of this Investor Deck. Readers should consider only these claims when evaluating this document.
Disclaimer

Except for the claims allowed by Health Canada Product Licenses 80000196, 80000364, 80000365, 80000477, 80000481, 80000504, 80000866, the Singapore Health Science Authority CDA (HSU) 40:43/01-B(V), the National Pharmaceutical Administration NPA (CPM) 6:06 /1 Vol 19, the Food and Drug Administration Authority (Republic of China) 0900027995, the Food and Drug Administration Authority (Peoples Republic of China) Import Food Hygiene Supervision and Inspection Bureau Certificate 990067, the Food and Drug Administration Authority Approval Number J20060001, neither Eastwood Bio-Medical Canada Inc., its affiliated companies, its employees, its distributors, nor its personnel make any claims that the products distributed by Eastwood Bio-medical Canada cure, diagnose, or, prevent any diseases.
Eastwood Bio-medical Canada Inc. (EBM) is not liable for any information provided on this Investor Deck with regard to recommendations regarding the mentioned products for any health purposes. The products or claims made about specific nutrients or products have not been evaluated by the United States Food and Drug Administration. Dietary products are not intended to treat, prevent or cure disease. Consult with a healthcare professional before starting any diet, supplement or exercise program. EBM makes no guarantee or warranty with respect to any products or services sold. EBM is not responsible for any damages for information provided by the Investor Deck even if EBM has been advised of the possibility of damages. Statements regarding potential health benefits from taking EBM products that appear on this website have not been evaluated by the FDA, and may not have been evaluated by any other governmental body.
Eastwood Bio-Medical Canada Inc. is located at Richmond, British Columbia, Canada near the Vancouver International Airport.
Canada has long been considered the global pioneer of the diabetes industry. In 1922, Frederick Grant Banting discovered insulin, which is considered one of the most important discoveries of the 20th century. The Nobel Foundation awarded his team the Nobel Prize in Physiology and Medicine in 1923.
Who We Are

A company specializing in metabolic disorders such as diabetes, obesity, hypertension, and Alzheimer’s disease.

We have successfully developed over 70 Eleotin® products including over 60 Health Canada (Canadian FDA) approved products.

Advertising Standards Canada (ASC) approved our flagship product, Eleotin® Bentley to be marketed as “World’s #1 Doctor recommended Natural Source Healthy Blood Glucose Promoting Product available in Canada”.

Please see Disclaimers on slides 3, 4, and 5.
Please see Disclaimers on slides 3, 4, and 5.
Who We Are

As of 2018, over 500,000 users are estimated to have used and benefited from Eleotin®. (An estimated 200,000 users as of 2014, or as of the ASC approval stamp)

More than four international health associations strongly recommend (endorsed) Eleotin®.

Eleotin® was the recipient of Best Diabetic & Hypertension Management Drug of the Year 2010*, and

7th Annual International Brand Packaging Gold Award.

*Institute for Government Research & Leadership Technology, Nigeria
Please see Disclaimers on slides 3, 4, and 5.
Company production capacity ‘recently’ has increased to:

- Up to 3 million capsules can be produced and 10,000 bottles can be packaged per day.
- A half million dollar worth of products in retail value can be produced daily.
- Up to $7 million in possible savings in annual manufacturing costs.
EBM: The Recent Focus of Financial Analysts and Investors
EBM: The Recent Focus of Financial Analysts and Investors

New Product Approvals and Licenses (68 NPN Numbers).
On June 29 2018, EBM announced entering binding terms for Asian exports. The Company is optimistic that this will result in an increase in revenues.

New manufacturing capabilities allow the Company to finally start producing highly advanced and complex products with the best quality and process control on a meaningfully larger scale.

The facilities and operations meet Good Manufacturing Practices standards, and retain site licenses from Health Canada and a foreign government.

EBM is no longer being bound by production limitations.
Stock Prices in the Past 6 Months

The market has begun paying attention.
Trading Volume in the Past 6 Months

629 K

Apr 9  May 14  Jun 11  Jul 9  Aug 6  Sep 3
Market Potential: Prevalence of Diabetes By IDF Region

Market Potential: Prevalence of Alzheimer’s and Dementia

Alzheimer’s and dementia patients worldwide

- World: 46.8m
- Americas: 9.4m
- Europe: 10.5m
- Africa: 4.0m
- Asia: 22.9m

World Alzheimer’s Report 2015
Market Potential: Prevalence of Hypertension

Global Prevalence of Hypertension over 1.3 Billion

- 29% EUROME & RUSSIA
- 25% SOUTH-EAST ASIA
- 30% EASTERN MEDITERRANEAN
- 26% WESTERN PACIFIC
- 37% AFRICA
- 23% AMERICAS

Global Health Observatory - WHO 2013
Market Values of Diabetes, Hypertension and Alzheimer’s

- Type 2 diabetes market to more than double, to $64 billion by 2026\(^1\)
- Global hypertension market will reach USD $32 billion by the end of 2020\(^2\)
- The global Alzheimer's market is expected to $10.4 billion in 2021\(^3\)

1. GlobalData’s report: PharmaPoint: Type 2 Diabetes – Global Drug Forecast and Market Analysis to 2026
2. Technavio
3. GBI Research - Alzheimer's Disease Therapeutics Market to 2021
Our Claim: The Only Option

We believe that our products are the ‘only’ natural sourced option for those inflicted with these diseases.

We also believe we will remain the only option in the near future.

Here is why…

Please see Disclaimers on slides 3, 4, and 5.
## Advantage #1: Modes of Action Known

<table>
<thead>
<tr>
<th>Pharmaceutical Drugs and Insulin</th>
<th>Other Herbal Products</th>
<th>Traditional Chinese Medicine</th>
<th>Folkloric Treatments/Alternative Treatments</th>
<th><strong>Eleotin®</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Known - Can be used with other pharmaceutical drugs</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
<td><strong>Known - Can be safely used with other pharmaceutical drugs</strong></td>
</tr>
</tbody>
</table>

- The Modes of Actions for most non-pharmaceutical treatments are unproven. They can not be used with pharmaceutical drugs out of fear of unknown adverse interactions.

- **Eleotin®'s** modes of actions are known and proven. **Eleotin®** is safe when used with oral pharmaceutical drugs and insulin.

- In fact, **Eleotin®** reduces the side effects and resistance of oral pharmaceutical drugs and insulin. When used with **Eleotin®**, oral pharmaceutical drugs and insulin become safer, more efficacious, and less habit forming.

Please see Disclaimers on slides 3, 4, and 5.
## Advantage #2: Long Term Effects

<table>
<thead>
<tr>
<th>Pharmaceutical Drugs and Insulin</th>
<th>Other Herbal Products</th>
<th>Traditional Chinese Medicine</th>
<th>Folkloric Treatments/Alternative Treatments</th>
<th>Eleotin®</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td>None</td>
<td>Unknown</td>
<td>None</td>
<td>Semi-permanent efficacy</td>
</tr>
</tbody>
</table>

- With proven insulin resistance reduction, Eleotin® provides semi-permanent long term improvement while other treatments do not give such long term benefits.
- Most other treatments only have short term control benefits, and must be used permanently.
- But a person can stop Eleotin® with no harmful side effects after the body has a attained structural change.

For more information, please contact info@eastwoodcos.com
Please see Disclaimers on slides 3, 4, and 5.
## Advantage #3: Preventive Effects

<table>
<thead>
<tr>
<th>Pharmaceutical Drugs and Insulin</th>
<th>Other Herbal Products</th>
<th>Traditional Chinese Medicine</th>
<th>Folkloric Treatments/Alternative Treatments</th>
<th><strong>Eleotin®</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
</tr>
</tbody>
</table>

- A person who does not have diabetes can use Eleotin® for general health and preventive purposes. Other treatments do not offer such safe options.

Please see Disclaimers on slides 3, 4, and 5.
## Conclusion

<table>
<thead>
<tr>
<th>Pharmaceutical Drugs and Insulin</th>
<th>Other Herbal Products</th>
<th>Traditional Chinese Medicine</th>
<th>Folkloric Treatments/Alternative Treatments</th>
<th>Eleotin®</th>
</tr>
</thead>
<tbody>
<tr>
<td>Short term and invasive treatment. Toxic and severe side effects. Resistance develops. Ever increasing dosages.</td>
<td>Shotgun approach. Most of them rely on artificial indigestion to lower the blood sugar.</td>
<td>Shotgun approach. Most of them rely on artificial indigestion to lower the blood sugar.</td>
<td>Shotgun approach. Most of them rely on artificial indigestion to lower the blood sugar.</td>
<td>Long term and safe beneficial effects. General health improvements.</td>
</tr>
</tbody>
</table>

- If you compare Eleotin® with other treatments from all perspectives, it’s natural to conclude that Eleotin® is the only natural sourced option.

Please see Disclaimers on slides 3, 4, and 5.
As a Result,

Advertising Standards Canada (ASC) approved Eleotin® to be marketed as “World’s #1 Doctor recommended Natural Source Healthy Blood Glucose Promoting Product available in Canada”.

- World’s No.1 Doctor recommended: Over 3000+ doctors
- Over 2,500 Newspaper & Television Acclaims (including New York Times #1 Best Sellers)
- Researched/Clinically tested by Universities and Governments
- Strongly recommended by more than 4 Associations
- Licenses issued by 8 Government Authorities
- Best Diabetic & Hypertension Management Drug of the Year 2010*
- As of 2018, more than 500,000 Users, and over 2,000 Youtube testimonials

*Institute for Government Research & Leadership Technology, Nigeria

Please see Disclaimers on slides 3, 4, and 5.
These are unsolicited third party opinions from unaffiliated individuals based on their own independent research. Except for claims referred to on slides 3, 4, and 5, EBM takes no responsibility for any claims.
Recommendations of Medical Professionals

Dr. Chu, Beijing China
"Because of Eleotin my husband doesn’t need any pharmaceutical drugs. He’s normal now."

Dr. L. Lipskaya, Bacteriologist
"After I started using Eleotin, I felt an improvement in my health conditions. Now I recommend Eleotin to every person who are suffering from Type II diabetes."

Dr. P. Singh
Ayurvedic Medicine
“I want to recommend Eleotin especially to Type II diabetics. It will help them in controlling their blood glucose levels.”

Dr. C. L. Broadhurst
“Eleotin is blend of many promising herbs that dramatically lower blood sugar.”

Dr. D. Walker
“Eleotin is effective in regulating blood glucose levels.”

Dr. M. Sichel
“A pathfinding discovery in the reversal of diabetes.”

Dr. E. Echano
“Everyone should know about this. I observed excellent clinical result. This unique herbal formulations long lasting effects are truly amazing.”

These are unsolicited third party opinions from unaffiliated individuals based on their own independent research. Except for claims referred to on slides 3, 4, and 5, EBM takes no responsibility for any claims.
SUCCESS IS JUST THAT SIMPLE
The Analysis Results of 300 Diabetics Cases

ELEOTIN has been on the market in North America for 8 years, and hundreds of thousands of diabetics are no longer suffering from diabetes because of it. In China, ELEOTIN has become well known, especially in neutralizing and adjusting/preventing complications from diabetes. ELEOTIN has shown great effectiveness.

To have a better understanding of ELEOTIN, we have done a detailed analysis by evaluating 300 diabetics. The 300 diabetics vary from ages 23 to 87. The period of time these patients took ELEOTIN varies from a short period of 1 month to a longer period of 8 months. Among these 300 cases, 256 were Type 2 diabetes (non-insulin dependent) and 44 were type 1 (insulin dependent).

Among the 256 patients with Type 2 diabetes, the blood glucose level (BGL) control and complications were different. Some of these patients had just recently been diagnosed, and others already had diabetes for decades. For these patients, some BGL were high during fasting, some were high 2 hours after meals, and some of them were high in both. Diabetics who were diagnosed for more than 5 years had one or more complications. In their clinical findings, symptoms of numbness and pain in the limbs and joints, fatigue, insomnia, skin itchiness, weak vision were present.

By taking ELEOTIN, 70% of these patients had stabilized their blood glucose level and 98% of their complications had improved. Some of them even had reduced dosage of pharmaceutical medications prescribed by physicians.

The following chart helps better explain the advantages of ELEOTIN:

1. This chart shows the percentage of people, Time taking ELEOTIN, and those with Reduced or Stopped Medication

<table>
<thead>
<tr>
<th>Time on ELEOTIN</th>
<th>Number of Persons</th>
<th>People with Reduced/Stopped Medications</th>
<th>Percentage of People</th>
</tr>
</thead>
<tbody>
<tr>
<td>Over 6 Months</td>
<td>96</td>
<td>62</td>
<td>64.6%</td>
</tr>
<tr>
<td>4 ~ 6 Months</td>
<td>142</td>
<td>59</td>
<td>41.5%</td>
</tr>
<tr>
<td>2 ~ 3 Months</td>
<td>40</td>
<td>5</td>
<td>12.6%</td>
</tr>
<tr>
<td>1 Months</td>
<td>22</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2. This chart shows the difference of symptoms and the BGL after taking ELEOTIN

<table>
<thead>
<tr>
<th>BGL &amp; Symptoms before taking ELEOTIN</th>
<th>Number of Persons</th>
<th>BGL &amp; Symptoms improved after taking ELEOTIN</th>
<th>Better Transitions</th>
</tr>
</thead>
<tbody>
<tr>
<td>High BGL</td>
<td>224</td>
<td>187</td>
<td>83.5%</td>
</tr>
<tr>
<td>BGL under control</td>
<td>32</td>
<td>32</td>
<td>100%</td>
</tr>
<tr>
<td>Insulin dependent</td>
<td>44</td>
<td>39</td>
<td>86.6%</td>
</tr>
<tr>
<td>Numbness on limb</td>
<td>56</td>
<td>47</td>
<td>83.9%</td>
</tr>
<tr>
<td>Fatigue</td>
<td>65</td>
<td>48</td>
<td>73.6%</td>
</tr>
<tr>
<td>Itchy skin</td>
<td>30</td>
<td>22</td>
<td>73%</td>
</tr>
<tr>
<td>Insomnia</td>
<td>34</td>
<td>25</td>
<td>73.5%</td>
</tr>
<tr>
<td>Weak vision</td>
<td>36</td>
<td>36</td>
<td>42.1%</td>
</tr>
<tr>
<td>Sweating</td>
<td>26</td>
<td>15</td>
<td>57.7%</td>
</tr>
<tr>
<td>Thirst</td>
<td>43</td>
<td>28</td>
<td>65.1%</td>
</tr>
<tr>
<td>Active urination at night</td>
<td>48</td>
<td>27</td>
<td>55.1%</td>
</tr>
<tr>
<td>Red swollen feet</td>
<td>3</td>
<td>2</td>
<td>66.7%</td>
</tr>
<tr>
<td>Impotence</td>
<td>7</td>
<td>6</td>
<td>85.7%</td>
</tr>
</tbody>
</table>

The above statistics are from an extensive analysis of the 300 diabetes cases. We are grateful to see the dramatic effectiveness of ELEOTIN according to the numbers shown with those who gain from the benefits. ELEOTIN will show its unique and powerful results to nourish and repair if given the time and patience. By decreasing or stopping intake of ELEOTIN before fully investing the time and effort, more than 70% of diabetics will maintain their BGL in normal or close to normalcy without bouncing back.

Such powerful result is due in part by its ability to alleviate insulin whose basic function is to control the amount of glucose in the blood. In doing so, ELEOTIN helps the establishment and repairing of B cells and increase in production of insulin. It can also balance the chemical reaction of insulin and beta cells and reduce the insulin resistance. By that the body will increase the metabolism of glucose.

Please see Disclaimers on slides 3, 4, and 5.
Clinical Studies, Publications, Approvals and Licenses

Comments on Eleotin® by the Korean National Diabetes Association

Please see Disclaimers on slides 3, 4, and 5.
Comments on Eleotin® by the Korean Pharmaceutical Manufacturers’ Association

Please see Disclaimers on slides 3, 4, and 5.
Africa's Best Diabetic & Hypertension Management Drug in 2010*

In the spirit of Nigeria’s 50th Independence celebration, Institute for Government Research & Leadership Technology have the honour to make this award in favour of ELEOTIN GP LTD having out performed other companies in the production of fine Diabetic pharmaceuticals in Nigeria.

1) Some of the parameters and performance indices used are:
- Your compliance with Government regulatory laws and guidelines;
- Your prowess and contribution in the production of drugs;
- Product’s high quality and value creation;
- Corporate Marketing strategy;
- Product’s price and pricing strategy;
- Product’s acceptability, satisfaction and endorsement;
- Corporate general performance and track record;
- Product’s unique selling points and competitive edge;
- Customer’s continued patronage and or referrals;

*These are unsolicited third party opinions based on independent research. Except for claims referred to on slides 3, 4, and 5, EBM takes no responsibility for any claims. Please see Disclaimers on slides 3, 4, and 5.
We have over 5,000 video testimonials on Youtube by users and doctors with all real names and many contact information to verify.

Please see Disclaimers on slides 3, 4, and 5.
Established Retail Lines

Eleotin® Bentley
- Helps promote healthy glucose levels.
- Long-term blood glucose normalization effects.
- General health improvement.

Eleotin® Ma5
- Powerful anti-oxidation powers that are preserved superbly.
- High quality Vitamin C group ingredients.
Established Retail Lines

**Eleotin® LBM**
- For hyperactivity of the liver (high blood pressure).
- To cut the vicious cycle between high blood sugar and high blood pressure caused by prescription drugs.

**Eleotin® Pedo-Protection Socks**
- Anti-Fungal & Anti-Bacterial.
- Auto Regulating Mesh Top.
- Treated Inner Toe Seam.
- Holistic & Gentle Neck Pressure.
Founder - Dr. Youngsoo Kim

- Advises Various Governments and senior management of numerous Korean firms including Hyundai, Gold Star, and Samsung
- CEO of Mutsumi Enterprises Canada Corp. 1991-1995
- Vice President of Toshin Butsuryu (Toyota Automobile Group Japan) 1991-1995
- Protocol secretary in the Korean Presidential Palace 1987
- Assistant Professor of Finance at the University of Alberta in Edmonton 1987
- Massachusetts Institute of Technology (Ph.D. in Economics) 1987
Board of Directors

Yunji Kim  
*President, CEO and Director*  
- President since April 2013, Director since October 2012  
- New York State Bar admission 2012  
- LL.M. in Taxation, Georgetown University Law Center, 2011

Peter Chen  
*CFO and Director*  
- Executive Director of Proterra Management Group Inc.

Dr. Marcus Kuypers  
*Director*  
- Medical Doctor  
- Physician at AB Staffing since November 2011  
- Accretive Health from October 2011 to February 2013  
- Doctors Home Visits from September 2001 to August 2011  
- Emergency Medicine physician since November 2011

Dr. Terrance Owen  
*Director*  
- Director of Pacific Paredyme Energy Inc.  
- CEO of CellMedX Corp.  
- President and CEO of Nuva Pharmaceuticals Inc. until June 2013
Appendix - Financial Information

Most updated information available upon request

www.eleotin.ca
TSX-V: EBM

Yunji Kim
Unit 1130-4871 Shell Road Richmond, B.C. Canada, V6X 3Z6
604.247.2100 or 1.888.669.4372
yunjikim@eastwoodcos.com
www.eleotin.ca